Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, treprostinil sodium (Trepulmix®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with WHO Functional Class (FC) III or IV and: inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. |
||
|
||
Medicine details |
||
| Medicine name | treprostinil sodium (Trepulmix®) | |
| Formulation | 1 mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml solution for infusion | |
| Reference number | 4086 | |
| Indication | Treatment of adult patients with WHO Functional Class (FC) III or IV and: inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity |
|
| Company | SciPharm Sarl | |
| BNF chapter | Respiratory system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 04/08/2020 | |